Innovative Therapeutics in Oncology and Neuroscience
KarXT
Schizophrenia, ADP
Expect Substantial Growth Over the Next Five Years
2023 2028
-
NEW LAUNCHES WITH
BLOCKBUSTER
POTENTIAL
Bemarituzumab
FGFR2b GC/GEJ
TTFields
NSCLC, NSCLC BM, PC
XACDURO®
ABC
50%
CAGR
2023-2028 Targeted
Revenue Growth
OTHER POTENTIAL NEAR-TERM DRUG LAUNCHES
BEFORE 2023...
ZEJULA®, OPTUNE®,
QINLOCK®, NUZYRAⓇ
VYVGARTⓇ
(efgartigimod alfa-fcab)
gMG*, CIDP, BP, TED
2023
tivdak
AUGTYRO
(repotrectinib)
KRAZATI®
Cervical cancer
ROS1 NSCLC, NTRK solid
tumors
KRAS G12C NSCLC, CRC
Abbreviations: generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), bullous pemphigoid (BP), thyroid eye disease (TED), acinetobacter baumannii-calcoaceticus complex (ABC), non-small cell lung
cancer (NSCLC), brain metastases from NSCLC (NSCLC BM), pancreatic cancer (PC), fibroblast growth factor receptor 2 (FGFR2b), gastric cancer (GC), gastroesophageal junction cancer (GEJ), Alzheimer's disease psychosis (ADP),
neurotrophic tropomyosin receptor kinase (NTRK), colorectal cancer (CRC).
5 Note: The trademarks and registered trademarks within are the property of their respective owners. Timeline is not drawn to scale. *Efgartigimod's first indication, gMG, launched in China in September 2023 with IV formulation.
2028
zaiLǝbView entire presentation